What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline

Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.

Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.